Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

Stock Information for Hepion Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.